Biocon tanks 10% on lower-than-expected December quarter results

Due to professional differences with the chairperson on strategic priorities and the vision for the company, Dr Christiane Hamacher has stepped down as the MD of Biocon Biologics

Biocon (Photo: Wikipedia)

The company's Ebitda declined 10.1 per cent YoY to Rs 400 crore in Q3FY21

Shares of Biocon plunged 10 per cent to Rs 400 on the BSE in the morning deals on Friday after the company posted below par December quarter (Q3FY21) results, with

Also Read

Biocon posts 19% dip in Q3 net profit as generics biz takes a hit

Biocon gains 2% after arm gets Rs 555 crore capital injection from ADQ

Biocon dips 11% in three days on disappointing September quarter results

Biocon: Street to keep an eye on CY21 launches, market share gains

Biocon-Mylan launch insulin Glargine at lowest price in US market

JK Tyre zooms 51% in 4 days, hits fresh 52-week high on robust Q3 results

Stocks to watch: RIL, YES Bank, Vedanta, HDFC Bank, SBI Card, Biocon

Market Ahead, January 22: All you need to know before the opening bell

Market Ahead, January 22: All you need to know before the opening bell

MARKETS: Sensex, Nifty decline, broader indices outperform; Biocon dips 10%

First Published: Jan 22 2021 | 10:09 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to